ReviewExpert review of anticancer therapy2022
Addressing the problem of overtreatment in breast cancer.
Review in Expert review of anticancer therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Mammography-Based Radiomics for Prediction of Nodal Status and Disease Burden in Breast Cancer: A Temporally Validated Study.Cancers · 2026Article
- Steroidogenic Acute Regulatory Protein in Breast Cancer: Mechanistic Insights into Pathogenesis and Therapeutics.International journal of molecular sciences · 2026Review
- Towards interpretable prediction of recurrence risk in breast cancer using pathology foundation models.NPJ digital medicine · 2026Article
- The role of circulating tumor cell-associated genes in the progression of estrogen receptor-positive breast cancer.NPJ breast cancer · 2025Article
- Less Is More: Risk Factors and Survival Outcomes of Overtreatment for Early-Stage Colorectal Cancer.Journal of surgical oncology · 2025Article
- Stepping Stones to Sustainability Within Cancer Clinical Trials in Ireland.Current oncology (Toronto, Ont.) · 2025Article
- Article
- Utility of systemic staging in breast cancer patients with a positive sentinel lymph node biopsy.Irish journal of medical science · 2025Article
- Prognosis, treatment decision-making and value: A qualitative exploration of the emerging role of breast cancer prognostic assays.PloS one · 2025Article
- Climate change and cancer care: impacts and implications for patients and healthcare professionals.Ecancermedicalscience · 2025Article
- Racial disparities in the frequency and timing of code status orders among women with breast cancer.BMC cancer · 2024Article
- Development and validation of a prognostic signature of breast cancer based on drug absorption, distribution, metabolism and excretion (ADME)-related genes.Scientific reports · 2024Article
- An Annual Symposium on Disparities in Milwaukee, WI, with a 2023 Focus on Older Adults with Cancer.Current oncology reports · 2024Review
- Avoiding Locoregional Overtreatment in Older Adults With Early-Stage Breast Cancer.Clinical breast cancer · 2024Review
- How to Optimize Deimplementation of Sentinel Lymph Node Biopsy?The breast journal · 2024Article
- Unsettling the treatment imperative? Chemotherapy decision-making in the wake of genomic techniques.Sociology of health & illness · 2023Article
- Clinical and Biological Aspects of Disseminated Tumor Cells and Dormancy in Breast Cancer.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
introductionAs breast cancer treatment options have multiplied and biologic diversity within breast cancer has been recognized, the use of the same treatment strategies for patients with early-stage and favorable disease, and for those with biologically aggressive disease, has been questioned. In addition, as patient-reported outcome measures have called attention to the morbidity of many common treatments, and as the cost of breast cancer care has continued to increase, reduction in the overtreatment of breast cancer has assumed increasing importance. AREAS COVERED: Here we review selected aspects of surgery, radiation oncology, and medical oncology for which scientific evidence supports de-escalation for invasive carcinoma and ductal carcinoma in situ, and assess strategies to address overtreatment. EXPERT OPINION: The problems of breast cancer overtreatment we face today are based on improved understanding of the biology of breast cancer and abandonment of the 'one-size-fits-all' approach. As breast cancer care becomes increasingly complex, and as our knowledge base continues to increase exponentially, these problems will only be magnified in the future. To continue progress, the move must be made from advocating the maximum-tolerated treatment to advocating the minimum-effective one.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.